Radius Health (NASDAQ:RDUS) is set to issue its Q2 2019 quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.86) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.01. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. The company had revenue of $29.84 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same period last year, the business earned ($1.11) EPS. Radius Health’s quarterly revenue was up 105.1% compared to the same quarter last year. On average, analysts expect Radius Health to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of NASDAQ:RDUS opened at $19.67 on Tuesday. The company has a current ratio of 5.16, a quick ratio of 5.04 and a debt-to-equity ratio of 6.75. The company’s fifty day moving average is $22.90. Radius Health has a 1-year low of $12.81 and a 1-year high of $25.40. The company has a market cap of $936.96 million, a PE ratio of -4.03 and a beta of 0.95.
RDUS has been the topic of several recent analyst reports. Citigroup restated a “neutral” rating and set a $24.00 price objective on shares of Radius Health in a research note on Thursday, May 30th. Goldman Sachs Group upgraded Radius Health from a “neutral” rating to a “buy” rating and raised their price objective for the company from $26.00 to $38.00 in a research note on Wednesday, May 29th. BidaskClub cut Radius Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 13th. Cowen restated a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Finally, Zacks Investment Research upgraded Radius Health from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, May 6th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $30.83.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.